

**Nobuo Okabe\* and Hiroko Saishu**

Faculty of Pharmaceutical Sciences, Kinki University, Kowakae 3-4-1, Higashiosaka, Osaka 577-8502, Japan

Correspondence e-mail: okabe@phar.kindai.ac.jp

**Key indicators**

Single-crystal X-ray study

$T = 296\text{ K}$

Mean  $\sigma(\text{C}-\text{C}) = 0.003\text{ \AA}$

$R$  factor = 0.033

$wR$  factor = 0.111

Data-to-parameter ratio = 13.2

For details of how these key indicators were automatically derived from the article, see <http://journals.iucr.org/e>.

**Bisaquabis(8-hydroxyquinolino-*N,O*)copper(II)**

The title compound,  $[\text{Cu}(\text{C}_9\text{H}_6\text{NO})_2(\text{H}_2\text{O})_2]$ , has a distorted octahedral geometry. The two *N,O*-bidentate ligand molecules lie in a *trans* geometry, in which the six-coordinate  $\text{Cu}^{\text{II}}$  ion lies on an inversion center.


Received 10 May 2001

Accepted 16 May 2001

Online 22 May 2001


**Comment**

8-Hydroxyquinoline (8-quinolinol, oxine) is a well known analytical reagent for forming chelate complexes with metal ions. Its metal complexes with copper(II), zinc(II) or nickel(II) have remarkable antimicrobial or fungicidal activity (Okide *et al.*, 2000; Patel *et al.*, 1999). The bismuth(III) complex has antitumor activity against leukaemia (Smith *et al.*, 1998). These results indicate that the metal complex of 8-hydroxyquinoline may be useful as a chemotherapeutic agent. Although the molecular mechanisms of the above activities are not yet clear, it is clear that the coordination geometry of these compounds plays an important role in their biological function. Although crystal structures of two types of copper(II) complexes of 8-hydroxyquinoline have been determined previously (Palenik, 1964; Hoy & Morriss, 1967), we have determined the structure of a different copper(II) complex, (I).



The molecular structure of (I) is shown in Fig. 1. The  $\text{Cu}^{\text{II}}$  ion is bonded to two N and two O atoms of the bidentate ligand molecules, forming two five-membered rings including the C7 and C8 atoms of the ligand molecule. The molecule has a distorted octahedral geometry. The two ligand molecules are centrosymmetrically related and the six-coordinate  $\text{Cu}^{\text{II}}$  ion lies on an inversion center of six-coordination. The  $\text{Cu}^{\text{II}}$  ion is bonded to two N atoms and two deprotonated O atoms of two ligand molecules which are located in a *trans* configuration with respect to each other, and also to two water O atoms in axial positions.

The  $\text{Cu1}-\text{O1}$  distance of  $1.966(2)\text{ \AA}$  is slightly shorter than the  $\text{Cu1}-\text{N1}$  distance of  $2.013(2)\text{ \AA}$ . This difference corresponds well to the difference of the Pauling's covalent radii



**Figure 1**  
ORTEP (Johnson, 1976) drawing of the title compound with the atomic numbering scheme. Ellipsoids for non-H atoms corresponding to 50% probability.

$r(\text{N}) = 0.70 \text{ \AA}$  and  $r(\text{O}) = 0.66 \text{ \AA}$ . The values found correspond well to the averages given by Orpen *et al.* (1989). The Cu1—O1 distance is somewhat longer than  $1.930 \text{ \AA}$  of the five-coordinate anhydrous copper(II) complex (Palenik, 1964) and  $1.939 \text{ \AA}$  of the six-coordinate anhydrous copper(II) complex (Hoy & Morriss, 1967). The Cu1—N1 distance is also longer than  $1.972 \text{ \AA}$  of the five-coordinate complex and  $1.984 \text{ \AA}$  of the six-coordinate one. On the other hand, the distance between Cu1 and the water O atom O2,  $2.41(2) \text{ \AA}$  is shorter than the corresponding Cu—O distances of the five-coordinate complex,  $2.830 \text{ \AA}$  (Palenik, 1964), and the six-coordinate one,  $3.324 \text{ \AA}$  (Hoy & Morriss, 1967).

## Experimental

The light-blue plate crystal was obtained by slow evaporation from a solution in ethanol–water (9:1) of a mixture containing 8-hydroxyquinoline and copper(II) chloride in a 5:1 molar ratio at room temperature.

### Crystal data

$[\text{Cu}(\text{C}_9\text{H}_6\text{NO})_2(\text{H}_2\text{O})_2]$	$D_x = 1.637 \text{ Mg m}^{-3}$
$M_r = 387.88$	Mo $K\alpha$ radiation
Monoclinic, $P2_1/a$	Cell parameters from 24 reflections
$a = 11.425(3) \text{ \AA}$	$\theta = 14.9\text{--}15.0^\circ$
$b = 5.542(3) \text{ \AA}$	$\mu = 1.42 \text{ mm}^{-1}$
$c = 12.950(4) \text{ \AA}$	$T = 296.2 \text{ K}$
$\beta = 106.39(2)^\circ$	Plate, light blue
$V = 786.7(5) \text{ \AA}^3$	$0.50 \times 0.40 \times 0.30 \text{ mm}$
$Z = 2$	

### Data collection

Rigaku AFC-5R diffractometer	$R_{\text{int}} = 0.011$
$\omega$ – $2\theta$ scans	$\theta_{\text{max}} = 27.5^\circ$
Absorption correction: $\psi$ scan (North <i>et al.</i> , 1968)	$h = 0 \rightarrow 14$
$T_{\text{min}} = 0.512$ , $T_{\text{max}} = 0.654$	$k = -7 \rightarrow 0$
2094 measured reflections	$l = -16 \rightarrow 16$
1813 independent reflections	3 standard reflections
1516 reflections with $I > 2\sigma(I)$	every 150 reflections
	intensity decay: 0.1%

### Refinement

Refinement on $F^2$	H-atom parameters not refined
$R[F^2 > 2\sigma(F^2)] = 0.033$	$w = 1/[\sigma^2(F_o^2) + (0.1P)^2]$
$wR(F^2) = 0.111$	where $P = (F_o^2 + 2F_c^2)/3$
$S = 0.91$	$(\Delta/\sigma)_{\text{max}} < 0.001$
1516 reflections	$\Delta\rho_{\text{max}} = 0.65 \text{ e \AA}^{-3}$
115 parameters	$\Delta\rho_{\text{min}} = -0.64 \text{ e \AA}^{-3}$

**Table 1**

Selected geometric parameters ( $\text{\AA}$ ,  $^\circ$ ).

Cu1—O1	1.966(2)	O1—C7	1.318(2)
Cu1—O2	2.451(2)	N1—C1	1.321(3)
Cu1—N1	2.013(2)	N1—C8	1.357(3)
O1—Cu1—O2	90.88(6)	C4—C5—C6	122.1(2)
O1—Cu1—N1	83.70(6)	C5—C6—C7	121.0(2)
O2—Cu1—N1	93.67(6)	O1—C7—C6	124.5(2)
Cu1—O1—C7	112.0(1)	O1—C7—C8	118.1(2)
Cu1—N1—C1	130.7(2)	C6—C7—C8	117.4(2)
Cu1—N1—C8	110.1(1)	N1—C8—C7	116.1(2)
C1—N1—C8	119.2(2)	N1—C8—C9	122.8(2)
N1—C1—C2	121.9(2)	C7—C8—C9	121.1(2)
C1—C2—C3	119.8(2)	C3—C9—C4	125.1(2)
C2—C3—C9	120.2(2)	C3—C9—C8	116.0(2)
C5—C4—C9	119.5(2)	C4—C9—C8	118.9(2)
O1—Cu1—N1—C1	178.4(2)	O2—Cu1—N1—C1	−91.2(2)
O2—Cu1—O1—C7	−92.9(1)	O2—Cu1—N1—C8	89.3(1)

**Table 2**

Hydrogen-bonding geometry ( $\text{\AA}$ ,  $^\circ$ ).

$D\cdots H\cdots A$	$D\cdots H$	$H\cdots A$	$D\cdots A$	$D\cdots H\cdots A$
O2—H7 $\cdots$ O1 <sup>i</sup>	0.89	1.94	2.829(2)	171
O2—H8 $\cdots$ O1 <sup>ii</sup>	0.77	2.07	2.839(2)	175

Symmetry codes: (i)  $x - \frac{1}{2}, \frac{1}{2} - y, z$ ; (ii)  $-x, 1 - y, -z$ .

All H atoms were located from difference Fourier maps and were not refined.

Data collection and cell refinement: *MSC/AFC Diffractometer Control Software* (Molecular Structure Corporation and Rigaku Corporation, 1999a); data reduction: *TEXSAN* (Molecular Structure Corporation and Rigaku Corporation, 1999b); program(s) used to solve structure: *SAPI91* (Fan, 1991); program(s) used to refine structure: *SHELXL97* (Sheldrick, 1997); molecular graphics: *ORTEP* (Johnson, 1976); software used to prepare material for publication: *TEXSAN*.

## References

- Fan, H.-F. (1991). *SAPI91*. Rigaku Corporation, Tokyo, Japan.
- Hoy, R. C. & Morriss, R. H. (1967). *Acta Cryst.* **22**, 476–482.
- Johnson, C. K. (1976). *ORTEP*. Report ORNL-5138. Oak Ridge National Laboratory, Tennessee, USA.
- Molecular Structure Corporation & Rigaku Corporation (1999a). *MSC/AFC Diffractometer Control Software*. MSC, 9009 New Trails Drive, The Woodlands, TX 77381–5209, USA, and Rigaku, 3–9–12 Akishima, Tokyo, Japan.
- Molecular Structure Corporation & Rigaku Corporation (1999b). *TEXSAN*. Version 1.10. MSC, 9009 New Trails Drive, The Woodlands, TX 77381–5209, USA, and Rigaku, 3–9–12 Akishima, Tokyo, Japan.
- North, A. C. T., Phillips, D. C. & Mathews, F. S. (1968). *Acta Cryst.* **A24**, 351–359.
- Okide, G. B., Adikwu, M. & Esimone, C. O. (2000). *Biol. Pharm. Bull.* **23**, 257–258.
- Orpen, A. G., Brammer, L., Allen, F. H., Kennard, O., Watson, D. G. & Taylor, R. (1989). *J. Chem. Soc. Dalton Trans.* pp. S1–S3.
- Palenik, G. J. (1964). *Acta Cryst.* **17**, 687–695.
- Patel, A. K., Patel, V. M., Patel, R. A., Sharma, S., Vora, J. J. & Joshi, J. D. (1999). *Synth. React. Inorg. Met. Org. Chem.* **29**, 193–204.
- Sheldrick, G. M. (1997). *SHELXL97*. University of Göttingen, Germany.
- Smith, K. A., Deacon, G. B., Jackson, W. R., Tiekinck, E. R. T., Rainone, S. & Webster, L. K. (1998). *Met. Based Drugs*, **5**, 295–304.